These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17344883)

  • 1. Toll-free vaccines?
    Krieg AM
    Nat Biotechnol; 2007 Mar; 25(3):303-5. PubMed ID: 17344883
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolls and beyond--many roads to vaccine immunity.
    Pulendran B
    N Engl J Med; 2007 Apr; 356(17):1776-8. PubMed ID: 17460233
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunology. Mouse studies question importance of toll-like receptors to vaccines.
    Wickelgren I
    Science; 2006 Dec; 314(5807):1859-60. PubMed ID: 17185572
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
    Kanzler H; Barrat FJ; Hessel EM; Coffman RL
    Nat Med; 2007 May; 13(5):552-9. PubMed ID: 17479101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taking a toll road to better vaccines.
    Morley SC; Allen PM
    Immunity; 2008 May; 28(5):602-4. PubMed ID: 18482564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
    Romagne F
    Drug Discov Today; 2007 Jan; 12(1-2):80-7. PubMed ID: 17198976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut flora, Toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine.
    Lundin A; Bok CM; Aronsson L; Björkholm B; Gustafsson JA; Pott S; Arulampalam V; Hibberd M; Rafter J; Pettersson S
    Cell Microbiol; 2008 May; 10(5):1093-103. PubMed ID: 18088401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptors and innate immunity in B-cell activation and antibody responses.
    Lanzavecchia A; Sallusto F
    Curr Opin Immunol; 2007 Jun; 19(3):268-74. PubMed ID: 17433875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor and pattern sensing for evoking immune response.
    Seya T
    Adv Drug Deliv Rev; 2008 Apr; 60(7):779-81. PubMed ID: 18336950
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic targeting of the innate immune system in domestic animals.
    Coffey TJ; Werling D
    Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The perfect mix: recent progress in adjuvant research.
    Guy B
    Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern recognition receptors and control of adaptive immunity.
    Palm NW; Medzhitov R
    Immunol Rev; 2009 Jan; 227(1):221-33. PubMed ID: 19120487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of innate immunity in the pathogenesis of asthma: evidence for the involvement of Toll-like receptor signaling.
    Schröder NW; Arditi M
    J Endotoxin Res; 2007; 13(5):305-12. PubMed ID: 17986489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology. Targeting the tolls.
    Wickelgren I
    Science; 2006 Apr; 312(5771):184-7. PubMed ID: 16614188
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii.
    Mayer ML; Phillips CM; Townsend RA; Halperin SA; Lee SF
    Scand J Immunol; 2009 Apr; 69(4):351-6. PubMed ID: 19284500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The importance of the second generation adjuvanted systems in "new" vaccines].
    Beran J
    Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smart adjuvants.
    Schmidt CS; Morrow WJ; Sheikh NA
    Expert Rev Vaccines; 2007 Jun; 6(3):391-400. PubMed ID: 17542754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.